Rapid recovery during VA-ECMO support remains a critical treatment goal in severe but potentially reversible cardiogenic shock. A multicenter randomized trial published in the Journal of the American Medical Association evaluated whether administering levosimendan within 48 hours of VA-ECMO initiation improves weaning success.

The study enrolled 205 adults across 11 French intensive care units between 2021 and 2024. Patients were randomized to receive levosimendan (n=101) or placebo (n=104). Postcardiotomy shock accounted for 38.5% of cases, with acute myocardial infarction (27.3%) and myocarditis (13.7%) also represented. Dose escalation to 0.20 μg/kg per minute was reached in 93% of the levosimendan group and 96% of the placebo group.

Within 30 days, successful weaning occurred in 68.3% of both groups (subdistribution hazard ratio 1.02; P=.92). Median ECMO duration was similar at 5 vs 6 days, and 60-day mortality remained comparable (27.7% vs 25.0%). However, ventricular arrhythmias were nearly twice as common with levosimendan (17.8% vs 8.7%).

These findings show that early levosimendan use does not improve VA-ECMO liberation and may introduce additional arrhythmia risk. Further research may identify patient subgroups who could benefit, but current evidence does not support routine early administration in this setting.